New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain

New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain

A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.